General Home Investors News Uzedy

25% Raise in 2024 UZEDY® Revenue Outlook & Key Milestone Reached for Olanzapine LAI clinical Phase 3

By MedincellNovember 6, 2024December 10th, 2024No Comments

25% Raise in 2024 UZEDY® Revenue Outlook & Key Milestone Reached for Olanzapine LAI clinical Phase 3

November 6, 2024

Previous PostVideoconference and publication of half-year financial results, Tuesday, December 10, 2024
Next PostNew Phase 3 Positive Results for Olanzapine LAI and Real-World Data on UZEDY®

Better medicine for all

Website by ScreenUp